Tadalafil
Most-read FDA actions from 2024 in pulmonology
Healio Pulmonology has compiled the top news from the FDA posted in 2024.
96% of patients with PAH prefer a single-tablet combination therapy
When presented with four unlabeled treatment profiles showing five treatment attributes, 96% of patients with pulmonary arterial hypertension chose a single-tablet vs. a multi-tablet combination therapy, according to a poster.
Combination macitentan, tadalafil tablet improves exercise capacity in PAH
SAN DIEGO — Exercise capacity improved among adults with pulmonary arterial hypertension taking a macitentan-tadalafil tablet over 68 weeks, according to research presented at the American Thoracic Society International Conference.
FDA approves combination therapy tablet for pulmonary arterial hypertension
The FDA has approved Opsynvi, a once-daily tablet that includes both macitentan and tadalafil, to treat adults with pulmonary arterial hypertension, according to a manufacturer-issued press release.
Benefit of upfront combination therapy not seen in low-risk PAH
Upfront combination therapy for patients with low-risk pulmonary arterial hypertension was not significantly better than monotherapy when assessing time to clinical worsening, according to results published in CHEST.
Topical gel for erectile dysfunction shows promise in phase 3 trial
An investigational therapy for erectile dysfunction met its primary and secondary endpoints in a confirmatory phase 3 clinical study, demonstrating significant improvements at 24 weeks, according to a press release from the manufacturer.
Low-risk status achieved or maintained in minority of patients on PAH combination therapy
In a new study, initial combination therapy for pulmonary arterial hypertension improved functional class and exercise capacity after 6 months, but low-risk status was achieved or maintained in only a minority of patients.
Initial triple therapy vs. double may improve outcomes in newly diagnosed PAH: TRITON
In patients with newly diagnosed pulmonary arterial hypertension, initial triple oral therapy, compared with double therapy, both improved hemodynamics, NT-proBNP and functional capacity, with no difference between strategies at 26 weeks.
Initial macitentan, tadalafil combination therapy shows promise for PAH: OPTIMA
NEW ORLEANS — Initial combination therapy with macitentan and tadalafil yielded hemodynamic and functional improvements and treatment was well tolerated in adults with newly diagnosed pulmonary arterial hypertension, according to data from the OPTIMA study.